Monopar Therapeutics Inc. (MNPR) vs Phathom Pharmaceuticals, Inc. (PHAT)
A side-by-side comparison of Monopar Therapeutics Inc. and Phathom Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
MNPR
Monopar Therapeutics Inc.
$81.74HealthcareDelayed quote: Oct 6, 2026, 2:40 PM EDT
PHAT
Phathom Pharmaceuticals, Inc.
$6.60HealthcareDelayed quote: Oct 6, 2026, 2:40 PM EDT
Total return — MNPR vs PHAT
growth of $100 · dividends reinvested · last 7yMNPR -40.9% (-7.2%/yr)PHAT -66.8% (-14.6%/yr)MNPR compounded faster over this window
MNPR PHAT
MNPR vs PHAT: by the numbers
- •MNPR is the larger company ($548M vs $534M market cap).
- •Both run net losses; MNPR's is the smaller (0.00% vs -41.34% net margin).
Metrics side by side
Valuation
| Metric | MNPR | PHAT |
|---|---|---|
| P/S ratio | N/A | 2.23 |
| P/B ratio | 4.18 | N/A |
Profitability
| Metric | MNPR | PHAT |
|---|---|---|
| Gross margin | 0.00% | 82.92% |
| Operating margin | 0.00% | -91.36% |
| Net margin | 0.00% | -41.34% |
| ROE | -13.64% | N/A |
| ROIC | -16.89% | -23.45% |
Growth (annualized)
| Metric | MNPR | PHAT |
|---|---|---|
| Total return CAGR (5Y) | 27.38% | -26.93% |
Frequently asked
- How have MNPR and PHAT total returns compared?
- Over the past 5 years, MNPR delivered 27.38% and PHAT delivered -26.93% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.